HeV sG V
Alternative Names: HeV vaccine; HeV-sG; HeV-sG-V; HeV-sG-V - Profectus Biosciences; NiV vaccineLatest Information Update: 28 Dec 2024
At a glance
- Originator Profectus Biosciences
- Developer Auro Vaccines; CSIRO; Profectus Biosciences
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Nipah virus infections; Viral infections
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Nipah-virus-infections(Prevention) in USA
- 30 Dec 2022 Phase-I development is ongoing in Nipah virus infections (Prevention) in USA (unspecified route) (NCT04199169)
- 06 May 2022 Auro Vaccines completes its phase I trial in Nipah virus infections (Prevention) in USA (unspecified route) (NCT04199169)